RxDoctor Payments Data

Nyingi Kemmer, MD

Transplant Hepatology · Tampa, FLNPI 1962468900

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $7,836 of the $10,748 with a category attached, or 72.9%. 7 manufacturers reported payments, led by Novo Nordisk at 49.0% of the total.

$10,748in general payments, 2019–2025

Across 18 payments — averaging $597.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$5K
  • Mirum Pharmaceuticals, Inc.$3K
  • Mallinckrodt Hospital Products Inc.$2K
  • Gilead$450
  • Exelixis Inc.$111
  • Mallinckrodt Enterprises LLC$73
  • plus $26 from 1 others
$415,555in research payments, 2019–2025

Across 155 payments — averaging $2681.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Intercept Pharmaceuticals, Inc.$192K
  • AbbVie$165K
  • E.r. Squibb & Sons, L.L.C.$39K
  • Pfizer$14K
  • Mallinckrodt Enterprises LLC$4K

What the payments were for

  • Consulting fees$7,83673%
  • Travel & lodging$2,02319%
  • Food & beverage$8888%

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few transplant hepatology providers in Floridato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$40,539
Medicare patients
226
Services billed
366

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin235$796,768
VemlidyTenofovir Alafenamide16$21,289
Ursodiol80$14,117
Tacrolimus48$7,072
Azathioprine25$1,909
Lactulose35$1,548
Mycophenolate Mofetil22$1,409
Nadolol15$340
Prednisone23$214
Spironolactone13$207
Propranolol Hcl19$96
Furosemide11$15

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadVemlidy$450$21,28916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few transplant hepatology providers in Floridaon file to place this against a meaningful peer group, so we don't.

Other transplant hepatology in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →